The Asia Pacific Microbial Fermentation Technology Market would witness market growth of 5.6% CAGR during the forecast period (2022-2028).
The fermentation process involves breaking big molecules into smaller ones or activating molecular oxidation/reduction pathways by particular microorganisms. From tiny laboratories to large industrial scale, fermentation technology creates various chemicals and depends on microbial components. This method also produces a variety of bioactive compounds, which have excellent positive effects on consumers' health.
Conjugated linolenic acid (CLA), vitamins, folate, and other beneficial components, for instance, have all been produced using different bacteria and yeast. Probiotic organisms are among the crucial subgroups of these microorganisms that participate in the fermentation process of various foods, including dairy products. When given to a host in adequate amounts, live microorganisms that have a positive impact on their health are known as probiotics.
Probiotics have been deemed "Generally Recognized As Safe" for consumption by people. They are known to have several positive health effects, including immunomodulatory, anti-cancer, anti-oxidant, cardioprotective, and anti-obese/diabetic. The formation of bioactive components during the fermentation process of meals is one of the many explanations for the bioactivity of probiotics on human health that have been put forth.
The demand for diverse goods made with microbial fermentation technology swill rise in the upcoming years due to an increase in per capita disposable income and a change in lifestyle in the emerging countries of the Asia Pacific region. The prevalence of chronic illnesses has increased along with the senior population. As a result, there will likely be an increase in the demand for this technology to allow for the release of new medications. An increasing requirement for various medications in the Asia Pacific region is also propelled by the increasing diabetes and cancer occurrences. All these factors support the regional market's growth in the coming years.
The China market dominated the Asia Pacific Microbial Fermentation Technology Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $5,184.8 million by 2028. The Japan market is estimated to grow a CAGR of 4.9% during (2022 - 2028). Additionally, The India market would display a CAGR of 6.2% during (2022 - 2028).
Based on Application, the market is segmented into Antibiotics, Recombinant Proteins, Enzymes, Monoclonal Antibodies, Probiotics Supplements, Vaccines, Biosimilars, Small Molecules and Others. Based on End User, the market is segmented into CMOs & CDMOs, Bio-Pharmaceutical Companies, Contract Research Organizations (CROs) and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Microbial Fermentation Technology Market is Projected to reach USD 42.4 Billion by 2028, at a CAGR of 5.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Biocon Limited, BioVectra Inc. (H.I.G. Capital, LLC), Danone S.A., F. Hoffmann-La Roche Ltd., Koninklijke DSM N.V., Lonza Group AG, Novozymes A/S (Novo Holdings A/S), Corbion N.V., and Bangalore Biotech Labs Pvt. Ltd. (BiOZEEN).
By Application
By End User
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
